What Future Holds for IR in Liver Cancer Space

Coordinator(s)

• 

  Nima Kokabi, MD

  Associate Professor of Radiology
  University of North Carolina - Chapel Hill, United States
• 

  Laura Crocetti, MD, PhD (she/her/hers)

  Associate Professor
  Università di Pisa, Italy

Presentations:

• 10:00 AM – 10:20 AM CT

  Should Y90 + systemic be the standard of care as first line treatment for ICC
  

  Speaker: Francesco De Cobelli, MD (he/him/his) – University Vita-Salute San Raffaele Milan
• 10:20 AM – 10:40 AM CT

  Radiation Segmentectomy: is it ready to replace ablation
  

  Speaker: Nora Tabori, MD (she/her/hers) – MedStar Washington Hospital Center

  Speaker: Constantinos T. Sofocleous, MD PhD – Weill Cornell Medical College Memorial Sloan-Kettering Cancer Center
• 10:40 AM – 11:00 AM CT

  Should IO + Immunotherapy be the standard of care for intermediate and advanced HCC in 2025? (IO + immunotherapy
  

  Speaker: Laura Crocetti, MD, PhD (she/her/hers) – Università di Pisa

  Speaker: Shamar Young, MD – University of Arizona
• 11:00 AM – 11:20 AM CT

  Will IR still play a major role in the care of HCC patients in 2035 in the era of more targeted therapies?
  

  Speaker: Hyo-Cheol Kim, MD – Seoul National University Hospital

  Speaker: David Madoff, MD, FSIR – Yale School of Medicine
• 11:20 AM – 11:30 AM CT

  Q&A